BEIJING (Reuters) – Chinese online drug retailer 111.dot Inc. began selling Pfizer Inc.’s oral COVID-19 treatment Paxlobide on Wednesday. This is believed to be the first time that Paxlobide has been sold to general consumers in China.
The price is 2,980 yuan ($426.80) per box, according to 111.dot’s website. You can purchase it on the app if you submit a positive result of the new corona test.
According to 111.dot customer service, it sold out an hour and a half after it was announced.
It is unclear how many boxes have been sold, when sales will resume, or whether other retailers will carry the product.
Paxlobide was approved in China in February and is available through hospitals in several provinces for the treatment of high-risk patients.
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/2PVQFW4CR5FI5GWZZGGS3JQX54.png)
